THROMBOSIS RESEARCH-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2198894, encodeId=331d219889406, content=偏重的研究方向：血栓 经验分享：前一天凌晨左右提交的，第二天7点多就被拒了，没给拒稿原因和审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53d49160543, createdName=ms8000000988880452, createdTime=Wed Apr 17 07:32:23 CST 2024, time=2024-04-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗？冠心病血瘀证多组学筛选后做了一些血小板自噬蛋白的验证，文章不是很深刻，有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：血栓;基础研究 经验分享：不难投稿，但是今年影响因子估计掉的很厉害！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0 经验分享：4月16号投稿，5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿一周， 返修后再审一周， 校样一周， 效率很高，很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投过两篇，中了两篇，很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0 经验分享：2021.08.01投的，2021.09.03就是All Reviews Completed，到现在也没结果，还在编辑手里，前两天发了催稿信，但是回复的都是套话，急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=)]

2024-04-17 ms8000000988880452 来自云南省

偏重的研究方向：血栓
经验分享：前一天凌晨左右提交的，第二天7点多就被拒了，没给拒稿原因和审稿意见

64 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198894, encodeId=331d219889406, content=偏重的研究方向：血栓 经验分享：前一天凌晨左右提交的，第二天7点多就被拒了，没给拒稿原因和审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53d49160543, createdName=ms8000000988880452, createdTime=Wed Apr 17 07:32:23 CST 2024, time=2024-04-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗？冠心病血瘀证多组学筛选后做了一些血小板自噬蛋白的验证，文章不是很深刻，有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：血栓;基础研究 经验分享：不难投稿，但是今年影响因子估计掉的很厉害！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0 经验分享：4月16号投稿，5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿一周， 返修后再审一周， 校样一周， 效率很高，很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投过两篇，中了两篇，很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0 经验分享：2021.08.01投的，2021.09.03就是All Reviews Completed，到现在也没结果，还在编辑手里，前两天发了催稿信，但是回复的都是套话，急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=)]

2023-07-28 1378327198@qq.com 来自湖南省

请问这个杂志收中医学基础研究的文章吗？冠心病血瘀证多组学筛选后做了一些血小板自噬蛋白的验证，文章不是很深刻，有没有可能投中啊。有没有希望🤣🤣

94 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198894, encodeId=331d219889406, content=偏重的研究方向：血栓 经验分享：前一天凌晨左右提交的，第二天7点多就被拒了，没给拒稿原因和审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53d49160543, createdName=ms8000000988880452, createdTime=Wed Apr 17 07:32:23 CST 2024, time=2024-04-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗？冠心病血瘀证多组学筛选后做了一些血小板自噬蛋白的验证，文章不是很深刻，有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：血栓;基础研究 经验分享：不难投稿，但是今年影响因子估计掉的很厉害！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0 经验分享：4月16号投稿，5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿一周， 返修后再审一周， 校样一周， 效率很高，很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投过两篇，中了两篇，很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0 经验分享：2021.08.01投的，2021.09.03就是All Reviews Completed，到现在也没结果，还在编辑手里，前两天发了催稿信，但是回复的都是套话，急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=)]

2023-02-14 ms4000002125344456 来自上海

请问网药哪些期刊友好呢？

121 0

[GetPortalCommentsPageByObjectIdResponse(id=2198894, encodeId=331d219889406, content=偏重的研究方向：血栓 经验分享：前一天凌晨左右提交的，第二天7点多就被拒了，没给拒稿原因和审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53d49160543, createdName=ms8000000988880452, createdTime=Wed Apr 17 07:32:23 CST 2024, time=2024-04-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗？冠心病血瘀证多组学筛选后做了一些血小板自噬蛋白的验证，文章不是很深刻，有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：血栓;基础研究 经验分享：不难投稿，但是今年影响因子估计掉的很厉害！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0 经验分享：4月16号投稿，5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿一周， 返修后再审一周， 校样一周， 效率很高，很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投过两篇，中了两篇，很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0 经验分享：2021.08.01投的，2021.09.03就是All Reviews Completed，到现在也没结果，还在编辑手里，前两天发了催稿信，但是回复的都是套话，急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=)]

2022-11-03 ms8000001235082561

请问met a分析这个期刊接收嘛？

100 0

[GetPortalCommentsPageByObjectIdResponse(id=2198894, encodeId=331d219889406, content=偏重的研究方向：血栓 经验分享：前一天凌晨左右提交的，第二天7点多就被拒了，没给拒稿原因和审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53d49160543, createdName=ms8000000988880452, createdTime=Wed Apr 17 07:32:23 CST 2024, time=2024-04-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗？冠心病血瘀证多组学筛选后做了一些血小板自噬蛋白的验证，文章不是很深刻，有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：血栓;基础研究 经验分享：不难投稿，但是今年影响因子估计掉的很厉害！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0 经验分享：4月16号投稿，5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿一周， 返修后再审一周， 校样一周， 效率很高，很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投过两篇，中了两篇，很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0 经验分享：2021.08.01投的，2021.09.03就是All Reviews Completed，到现在也没结果，还在编辑手里，前两天发了催稿信，但是回复的都是套话，急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=)]

2022-09-15 ms3000000928163054

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：血栓;基础研究
经验分享：不难投稿，但是今年影响因子估计掉的很厉害！

116 0

[GetPortalCommentsPageByObjectIdResponse(id=2198894, encodeId=331d219889406, content=偏重的研究方向：血栓 经验分享：前一天凌晨左右提交的，第二天7点多就被拒了，没给拒稿原因和审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53d49160543, createdName=ms8000000988880452, createdTime=Wed Apr 17 07:32:23 CST 2024, time=2024-04-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗？冠心病血瘀证多组学筛选后做了一些血小板自噬蛋白的验证，文章不是很深刻，有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：血栓;基础研究 经验分享：不难投稿，但是今年影响因子估计掉的很厉害！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0 经验分享：4月16号投稿，5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿一周， 返修后再审一周， 校样一周， 效率很高，很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投过两篇，中了两篇，很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0 经验分享：2021.08.01投的，2021.09.03就是All Reviews Completed，到现在也没结果，还在编辑手里，前两天发了催稿信，但是回复的都是套话，急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=)]

2022-05-29 ms9000001396467020

审稿速度:2.0
经验分享：4月16号投稿，5月29日仍然是under review是正常的吗

131 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198894, encodeId=331d219889406, content=偏重的研究方向：血栓 经验分享：前一天凌晨左右提交的，第二天7点多就被拒了，没给拒稿原因和审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53d49160543, createdName=ms8000000988880452, createdTime=Wed Apr 17 07:32:23 CST 2024, time=2024-04-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗？冠心病血瘀证多组学筛选后做了一些血小板自噬蛋白的验证，文章不是很深刻，有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：血栓;基础研究 经验分享：不难投稿，但是今年影响因子估计掉的很厉害！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0 经验分享：4月16号投稿，5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿一周， 返修后再审一周， 校样一周， 效率很高，很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投过两篇，中了两篇，很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0 经验分享：2021.08.01投的，2021.09.03就是All Reviews Completed，到现在也没结果，还在编辑手里，前两天发了催稿信，但是回复的都是套话，急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=)]

2022-03-31 wangzzzzzzz

审稿速度:1.0 | 投稿命中率:50.0
经验分享：审稿一周，
返修后再审一周，
校样一周，
效率很高，很友好

118 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198894, encodeId=331d219889406, content=偏重的研究方向：血栓 经验分享：前一天凌晨左右提交的，第二天7点多就被拒了，没给拒稿原因和审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53d49160543, createdName=ms8000000988880452, createdTime=Wed Apr 17 07:32:23 CST 2024, time=2024-04-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗？冠心病血瘀证多组学筛选后做了一些血小板自噬蛋白的验证，文章不是很深刻，有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：血栓;基础研究 经验分享：不难投稿，但是今年影响因子估计掉的很厉害！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0 经验分享：4月16号投稿，5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿一周， 返修后再审一周， 校样一周， 效率很高，很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投过两篇，中了两篇，很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0 经验分享：2021.08.01投的，2021.09.03就是All Reviews Completed，到现在也没结果，还在编辑手里，前两天发了催稿信，但是回复的都是套话，急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=)]

2018-06-28 m201776035_66684584

请问这个是需要所有作者都注册杂志账号才能投稿吗？

443 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198894, encodeId=331d219889406, content=偏重的研究方向：血栓 经验分享：前一天凌晨左右提交的，第二天7点多就被拒了，没给拒稿原因和审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53d49160543, createdName=ms8000000988880452, createdTime=Wed Apr 17 07:32:23 CST 2024, time=2024-04-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗？冠心病血瘀证多组学筛选后做了一些血小板自噬蛋白的验证，文章不是很深刻，有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：血栓;基础研究 经验分享：不难投稿，但是今年影响因子估计掉的很厉害！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0 经验分享：4月16号投稿，5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿一周， 返修后再审一周， 校样一周， 效率很高，很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投过两篇，中了两篇，很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0 经验分享：2021.08.01投的，2021.09.03就是All Reviews Completed，到现在也没结果，还在编辑手里，前两天发了催稿信，但是回复的都是套话，急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=)]

2018-09-22 1321f1834cm

审稿速度:2.0 | 投稿命中率:95.0
经验分享：投过两篇，中了两篇，很友好的杂志。

410 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198894, encodeId=331d219889406, content=偏重的研究方向：血栓 经验分享：前一天凌晨左右提交的，第二天7点多就被拒了，没给拒稿原因和审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53d49160543, createdName=ms8000000988880452, createdTime=Wed Apr 17 07:32:23 CST 2024, time=2024-04-17, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2150272, encodeId=92d721502e225, content=请问这个杂志收中医学基础研究的文章吗？冠心病血瘀证多组学筛选后做了一些血小板自噬蛋白的验证，文章不是很深刻，有没有可能投中啊。有没有希望🤣🤣 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Jul 28 16:40:57 CST 2023, time=2023-07-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2114572, encodeId=7cdd21145e27e, content=请问网药哪些期刊友好呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdad8313583, createdName=ms4000002125344456, createdTime=Tue Feb 14 14:17:56 CST 2023, time=2023-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2098282, encodeId=c103209828240, content=请问met a分析这个期刊接收嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd328357226, createdName=ms8000001235082561, createdTime=Thu Nov 03 16:50:11 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249119, encodeId=b02712491192a, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：血栓;基础研究 经验分享：不难投稿，但是今年影响因子估计掉的很厉害！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89156432050, createdName=ms3000000928163054, createdTime=Thu Sep 15 16:56:56 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223144, encodeId=b05e12231442e, content=审稿速度:2.0 经验分享：4月16号投稿，5月29日仍然是under review是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21515562473, createdName=ms9000001396467020, createdTime=Sun May 29 12:40:23 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207436, encodeId=e91d120e43699, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿一周， 返修后再审一周， 校样一周， 效率很高，很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJaicGoPL4gRLibjrGJ6NViacZ9ZhGgUVTU3cClwuaUqUjB2BBSHqiaMknDicckus13ZHgf1t8XBqS5gAw/132, createdBy=cfc11961463, createdName=wangzzzzzzz, createdTime=Thu Mar 31 09:12:29 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558597, encodeId=bc4b55859e24, content=请问这个是需要所有作者都注册杂志账号才能投稿吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8ce2392456, createdName=m201776035_66684584, createdTime=Thu Jun 28 22:16:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561362, encodeId=19a65613623c, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：投过两篇，中了两篇，很友好的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33912077822, createdName=1321f1834cm, createdTime=Sat Sep 22 00:00:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058447, encodeId=e195105844e98, content=审稿速度:3.0 经验分享：2021.08.01投的，2021.09.03就是All Reviews Completed，到现在也没结果，还在编辑手里，前两天发了催稿信，但是回复的都是套话，急着毕业啊~难受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ea75535350, createdName=ms3000001155211603, createdTime=Thu Oct 07 20:22:37 CST 2021, time=2021-10-07, status=1, ipAttribution=)]

2021-10-07 ms3000001155211603

审稿速度:3.0
经验分享：2021.08.01投的，2021.09.03就是All Reviews Completed，到现在也没结果，还在编辑手里，前两天发了催稿信，但是回复的都是套话，急着毕业啊~难受

146 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务